Dyne Therapeutics Inc (DYN) concluded trading on Wednesday at a closing price of $8.88, with 5.69 million shares of worth about $50.51 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -64.14% during that period and on July 09, 2025 the price saw a gain of about 5.84%. Currently the company’s common shares owned by public are about 113.63M shares, out of which, 106.14M shares are available for trading.
Stock saw a price change of 2.30% in past 5 days and over the past one month there was a price change of -39.59%. Year-to-date (YTD), DYN shares are showing a performance of -74.19% which decreased to -62.31% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.36 but also hit the highest price of $47.45 during that period. The average intraday trading volume for Dyne Therapeutics Inc shares is 2.86 million. The stock is currently trading -17.85% below its 20-day simple moving average (SMA20), while that difference is down -23.21% for SMA50 and it goes to -52.84% lower than SMA200.
Dyne Therapeutics Inc (NASDAQ: DYN) currently have 113.63M outstanding shares and institutions hold larger chunk of about 67.33% of that.
The stock has a current market capitalization of $1.26B and its 3Y-monthly beta is at 1.09. It has posted earnings per share of -$3.59 in the same period. It has Quick Ratio of 20.35 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DYN, volatility over the week remained 6.96% while standing at 7.41% over the month.
Stock’s fiscal year EPS is expected to drop by -16.12% while it is estimated to increase by 1.42% in next year. EPS is likely to grow at an annualized rate of -0.41% for next 5-years, compared to annual growth of -59.45% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Bernstein on June 24, 2025 offering a Mkt perform rating for the stock and assigned a target price of $13 to it. Coverage by Raymond James stated Dyne Therapeutics Inc (DYN) stock as an Outperform in their note to investors on June 11, 2025, suggesting a price target of $37 for the stock. On June 02, 2025, Oppenheimer Resumed their recommendations, while on May 29, 2025, Evercore ISI Initiated their ratings for the stock with a price target of $46. Stock get an Outperform rating from BMO Capital Markets on March 12, 2025.
